Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

Immutep Ltd. Stock

Price
Target price
€0.24

€0.24

-11.110%
-0.03
-11.110%
-
 
25.04.24 / Stuttgart Stock Exchange WKN: A2H81H / Symbol: PRRUF / Name: Immutep / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Immutep Ltd. in the next few years
Wizard

Immutep Ltd. Stock

Immutep Ltd. took a tumble today and lost -€0.030 (-11.110%).
What does Immutep do?

Pros and Cons of Immutep Ltd. in the next few years

Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Immutep Ltd. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Immutep Ltd. -11.110% 31.068% 20.536% 81.208% 29.808% 0.372% 107.692%
TALI Digital Ltd. - 0.000% 0.000% -66.667% 0.000% -98.113% -92.857%
Alterity Therapeutics Ltd. ADR - 1.235% 26.154% -28.070% -20.388% -85.614% -88.506%
Invion Ltd - 0.000% 100.000% -42.857% 33.333% -55.556% -71.429%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-17

Immutep (US symbol: PRRUF) operates in the Biotechnology & Medical Research industry and has experienced fluctuations in its financial performance over the years. The company has shown a steady growth in total assets and reduced its liabilities, attributing to a boost in its overall financial position. However, Immutep is still incurring losses, indicative of the inherent challenges and uncertainties within the biotechnology and medical research industry.

Increasing Total Assets: Immutep's total assets have grown consistently from AUD 46.6 million in 2020 to AUD 82.03 million in 2021, and further to AUD 102.17 million in 2022. This growth can be attributed to increasing cash holdings and other current assets, reflecting the company's ability to expand its operations and research projects.

Decreasing Liabilities: The company has showcased a considerable reduction in total liabilities over the years. It went down from AUD 13.3 million in 2020 to AUD 8.76 million in 2021 and further to AUD 8.09 million in 2022. This reduction in liabilities strengthens Immutep's financial stability and lowers the financial risk.

Show more
Register To Post